Alkermes (ALKS) Interest & Investment Income (2010 - 2026)
Alkermes (ALKS) posted quarterly Interest & Investment Income of $5.3 million for Q2 2026, down 51.81% year-over-year from $11.1 million in Q2 2025, and up 1040.85% quarter-over-quarter from -$568000.0 in Q1 2026.
Alkermes (ALKS) Interest & Investment Income (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Interest & Investment Income for 17 consecutive years, with $5.3 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Interest & Investment Income fell 51.81% year-over-year to $5.3 million; the TTM figure through Jun 2026 stood at $28.8 million (down 14.94% YoY), while the FY2025 annual figure was $45.3 million, up 6.72% from the prior year.
- Interest & Investment Income advanced to $5.3 million in Q2 2026 per ALKS's latest filing, from -$568000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $16.7 million in Q4 2022 and bottomed at -$4.5 million in Q1 2022.
- Historically, Interest & Investment Income has averaged $5.1 million across 5 years, with a median of $4.1 million in 2023.
- Annual changes were most pronounced in 2022 — Interest & Investment Income slumped 728.68% — and 2025, when it jumped 100718.18%.
- Alkermes' Interest & Investment Income stood at $16.7 million in 2022, then slumped by 41.77% to $9.7 million in 2023, then increased by 16.94% to $11.4 million in 2024, then climbed by 6.4% to $12.1 million in 2025, then tumbled by 55.94% to $5.3 million in 2026.
- Business Quant data shows ALKS's Interest & Investment Income at $5.3 million in Q2 2026, -$568000.0 in Q1 2026, and $12.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.21 Bn | 39.55 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.74 Bn | 30.06 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | 154.39 Mn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 31.50 Mn |
| 6 | Viatris | 18.80 Bn | 17.91 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.70 Bn | 15.31 Bn | 935.80 Mn | 12.40 Mn |
| 8 | Elanco Animal Health | 12.14 Bn | 11.61 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.17 Bn | 10.01 Bn | - | - |
| 10 | Alkermes | 8.23 Bn | 7.57 Bn | 397.90 Mn | 5.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.34 Mn |
| Mar 31, 2026 | -568,000.00 |
| Dec 31, 2025 | 12.13 Mn |
| Sep 30, 2025 | 11.94 Mn |
| Jun 30, 2025 | 11.09 Mn |
| Mar 31, 2025 | 512,000.00 |
| Dec 31, 2024 | 11.40 Mn |
| Sep 30, 2024 | 10.92 Mn |
| Jun 30, 2024 | 11,000.00 |
| Mar 31, 2024 | -491,000.00 |
| Dec 31, 2023 | 9.75 Mn |
| Sep 30, 2023 | 9.37 Mn |
| Jun 30, 2023 | 692,000.00 |
| Mar 31, 2023 | 2.76 Mn |
| Dec 31, 2022 | 16.74 Mn |
| Sep 30, 2022 | -2.35 Mn |
| Jun 30, 2022 | -2.25 Mn |
| Mar 31, 2022 | -4.51 Mn |
| Dec 31, 2021 | 453,000.00 |
| Sep 30, 2021 | 468,000.00 |